PLRX vs HALO vs ALNY vs ARWR vs IONS

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 33. 9% for Ionis Pharmaceuticals, Inc. (IONS). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 27. 1x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Halozyme Therapeutics, Inc. (HALO) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 27. 1x versus Alnylam Pharmaceuticals, Inc. at 121. 4x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 6x.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +93. 9%, compared to -96. 6% for Pliant Therapeutics, Inc. (PLRX). Over 10 years, the gap is even starker: ARWR returned +1170% versus PLRX's -94. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 42β versus Arrowhead Pharmaceuticals, Inc. 's 1. 69β — meaning ARWR is approximately 304% more volatile than IONS relative to the S&P 500. On balance sheet safety, Pliant Therapeutics, Inc. (PLRX) carries a lower debt/equity ratio of 16% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 33. 9% for Ionis Pharmaceuticals, Inc. (IONS). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -40. 5% for IONS. At the gross margin level — before operating expenses — ARWR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 6x forward P/E versus 37. 7x for Alnylam Pharmaceuticals, Inc. — 29. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 57. 6% to $445. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 58), +701. 6% 10Y return). Both have compounded well over 10 years (HALO: +701. 6%, PLRX: -94. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLRX is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock; ARWR is a mid-cap high-growth stock; IONS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.